HIV

The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.

Latest News

PrEP | Image credit: wladimir1804 - stock.adobe.com
Elimination of HIV Prevention Division Being Considered by Trump Administration

March 20th 2025

The HIV prevention division could be rolled into another department of the HHS as soon as the end of the week.

Different forms of ART | Image credit: jarun011 - stock.adobe.com
Long-Acting Injectable Cabotegravir Effective in Both ART, PrEP

March 12th 2025

ART | Image credit: Sakdatorn - stock.adobe.com
DTG/3TC, Fostemsavir Effective as ART for Patients With HIV

March 12th 2025

HIV self-test | Image credit: Courtney Haas/peopleimages.com - stock.adobe.com
Self-Testing in HIV Shows Promise in Early Studies

March 11th 2025

HIV | Image credit: reddish - stock.adobe.com
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session

March 10th 2025

Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

This discussion focuses on how to address barriers and disparities as obstacles to using PrEP, with a focus on USPSTF PrEP guidelines and ACA Part 47 for payers and providers.

This multi-stakeholder roundtable panel discussion will focus on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force (USPSTF) PrEP guidelines and Affordable Care Act Part 47 for payers and providers.
Continuing Medical Education
View All
March 20th 2025

Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence

1.5 Credits / HIV/AIDS, Infectious Diseases

More News

Triple Therapy Maintains HIV Viral Suppression in Patients With Mutation, Prior Virologic Failure
November 25th 2022

Triple Therapy Maintains HIV Viral Suppression in Patients With Mutation, Prior Virologic Failure

Hayden E. Klein
According to the study authors, bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) may be an option for simplification following viral suppression.
Long-Acting Injectables Promote PrEP Access, Adherence, Says Dr Tam Phan
November 22nd 2022

Long-Acting Injectables Promote PrEP Access, Adherence, Says Dr Tam Phan

Hayden E. Klein
Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.
Jana Dickter, MD
November 16th 2022

Stem Cell Transplant May Be Viable Treatment for Patients With HIV, Leukemia, Says Dr Jana Dickter

Hayden E. Klein Skylar Jeremias
Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, discusses a patient's experience being the oldest person to successfully undergo a stem cell transplant while living with HIV and leukemia.
group of people wearing white t shirts and red HIV ribbons
November 3rd 2022

Earlier ART Linked to Better Long-term HIV Outcomes

Hayden E. Klein
An extended follow-up to a 2015 study further supports that beginning antiretroviral therapy (ART) earlier is linked to better long-term outcomes compared with delayed ART initiation.
What We're Reading
October 27th 2022

What We’re Reading: State Determines Health Outcomes; Increasing Comorbid HIV/Monkeypox Infection; More Children Uninsured

AJMC Staff
A recent study found that Americans die younger in states with conservative policies; most patients admitted to the hospital with monkeypox also have HIV; 4 million children are uninsured due to state policies, according to new research.
Kevin Astle, PharmD
October 25th 2022

Dr Kevin Astle on the Pharmacist's Role in PrEP Accessibility, Adherence

Hayden E. Klein
Pharmacists must take time to understand why patients are not adherent to HIV pre-exposure prophylaxis (PrEP) and what barriers exist, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
HIV and Blood Cancers: The City of Hope Patient
October 21st 2022

HIV and Blood Cancers: The City of Hope Patient

Mary Caffrey
A featured presentation at the Irvine, California, meeting of the Institute for Value-Based Medicine discussed how a patient with long-term HIV was cured through a transplant.
Jana K. Dickter, MD
October 19th 2022

Dr Jana Dickter Talks About Developments in HIV Treatment, Management

Hayden E. Klein Skylar Jeremias
HIV antiretroviral therapy has changed and improved dramatically since it first became available, said Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope.
HIV Awareness.
October 14th 2022

Examining Cost-effectiveness, Efficacy of Combination Therapies in HIV

Matthew Gavidia
Two posters presented at AMCP Nexus 2022 addressed the cost-effectiveness of guideline-recommended integrase strand transfer inhibitor–based triple therapy in people living with HIV, as well as the efficacy of adjuvant lenacapavir in treatment-naïve patients.
Kevin Astle, PharmD
October 13th 2022

Dr Kevin Astle Discusses Therapies in HIV PrEP Pipeline and Trends in Access, Adherence

Hayden E. Klein
Kevin N. Astle, PharmD, assistant professor at University of South Florida Taneja College of Pharmacy, expands on HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline discussed at the Academy of Managed Care Pharmacy Nexus fall 2022 meeting.
David Koren, PharmD
October 6th 2022

Dr David Koren: It's Important for Providers to Empower Patients With HIV

Hayden E. Klein
David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, emphasizes the importance of patients with HIV and providers working together.
doctor prepping vaccine
October 4th 2022

Third COVID-19 Vaccine Dose Yields Higher Immune Protection in PLWH

Hayden E. Klein
Results of a study among persons living with HIV (PLWH) in Hong Kong showed that a 3-dose primary COVID-19 vaccine series improved immune protection.
Picture of author M. "Tonette" Krouser-Wood
September 27th 2022

Contributor: Every Day Is HIV Awareness Day—The Importance of Motivating People to Get Tested for HIV

M. "Tonette" Krousel-Wood, MD, MSPH, FACPM
David E. Koren, PharmD, MPH
September 22nd 2022

Dr David Koren Discusses Barriers to Implementing Long-Acting Injectables for HIV

Hayden E. Klein
David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, explains the barriers both patients and providers face in implementing long-acting injectables for HIV.
What We're Reading
September 14th 2022

What We’re Reading: AMA Joins Class-Action Lawsuit; Monkeypox Brain Inflammation; San Francisco HIV Cases

AJMC Staff
The American Medical Association (AMA) and 2 state medical societies joined a class-action lawsuit against Cigna for underpaying claims filed by providers; 2 cases of monkeypox have led to brain inflammation; for the first time, gay and bisexual men make up less than half of new HIV cases in San Francisco.
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre
September 10th 2022

Dr Anchalee Avihingsanon: We Can Learn About Curing Hepatitis B From Investigating HIV

Maggie L. Shaw
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial, currently evaluating the responses of treatment-naïve persons living with comorbid HIV/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.
man filling out survey
September 7th 2022

Survey Reveals Injectable HIV PrEP Preferences of Young Men Who Have Sex With Men

Hayden E. Klein
Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and delivery method.
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre
September 3rd 2022

Dr Anchalee Avihingsanon: We Need More Study on Hep B Endurance in PLWH

Maggie L. Shaw
The ALLIANCE trial is investigating the responses of treatment-naïve persons living with comorbid HIV (PLWH)/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.
tablet with video of doctor
September 1st 2022

Tailored Video Doctor Intervention May Benefit Certain PLWH

Hayden E. Klein
A highly tailored video doctor intervention was shown to help men living with HIV achieve viral suppression, and younger and older patients achieve HIV care retention.
group of 5 people standing, wearing white shirts and red HIV ribbons
August 30th 2022

Immune Responses to ART Vary by Regimen Among Individuals With Advanced HIV

Hayden E. Klein
People with advanced HIV initiating bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were more likely to reach CD4 cell count levels of 200 cells/mcL or higher compared with those initiating other antiretroviral therapy (ART) regimens.
group of 5 teens sitting and talking to each other
August 25th 2022

Confidentiality Protections for Minors Seeking STI, HIV Services Vary Across US

Hayden E. Klein
Patient confidentiality is a major reason why minors do not seek out prevention, testing, and treatment services for sexually transmitted infections (STIs) and HIV.
rainbow ribbon wrapped around stethoscope
August 22nd 2022

Black, Latinx Transgender Women Cite Multiple Motivations for PrEP Use

Hayden E. Klein
Black and Latinx transgender women expressed high levels of HIV risk perception at the individual and community level, both of which played major roles in their decision to start and continue pre-exposure prophylaxis (PrEP).
group of animated people connected by lines
August 20th 2022

CDC Provides Interim Guidance for Treatment, Prevention of Monkeypox Among PLWH

Hayden E. Klein
The guidance focuses on treatment with tecovirimat, pre-exposure prophylaxis and postexposure prophylaxis with the Jynneos monkeypox vaccine, and infection control among persons living with HIV (PLWH).
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre
August 16th 2022

Dr Anchalee Avihingsanon Addresses Trial Diversity Recruitment Difficulties

Maggie L. Shaw
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, Midwestern University College of Pharmacy
August 13th 2022

Contributor: It’s Important to Prioritize HIV Care During the COVID-19 Pandemic

Allison Fortier Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Not all barriers to HIV-related care and services have been eliminated, and these gaps in care were exacerbated by treatment disruptions brought on by the COVIDC-19 pandemic.
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre,
August 7th 2022

Dr Anchalee Avihingsanon Discusses Treatment as Prevention for HIV/HBV Coinfection

Maggie L. Shaw
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial from Gilead.
HIV test tube
August 4th 2022

HIV, STI Testing Rates Too Low in Southeast Michigan

Hayden E. Klein
New study findings show suboptimal HIV and sexually transmitted infection (STI) testing rates among sexual and gender minority individuals in the state, contrary to CDC guidelines.
What We're Reading
August 1st 2022

What We’re Reading: US Polio Case Origins Detected; HIV-Positive Heart Transplant Performed; NC Considering Medicaid Expansion

AJMC Staff
The first case of polio in the United States in nearly a decade demonstrated a potential link to vaccine-derived viruses in Jerusalem and London; the world’s first HIV-positive heart transplant has been performed in the Bronx; North Carolina is on the path to Medicaid expansion.
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre
July 29th 2022

Dr Anchalee Avihingsanon: ALLIANCE Trial Findings Are Meaningful for HIV/HBV Coinfection

Maggie L. Shaw
The ALLIANCE trial is the first randomized blinded trial to investigate tenofovir alafenamide vs tenofovir disoproxil fumarate in treatment-naive individuals who have comorbid HIV/hepatitis B virus (HBV) infection.
City of Hope logo
July 27th 2022

After Transplant, City of Hope Patient in Long-term Remission From HIV and Leukemia

Mary Caffrey
City of Hope has announced that a patient living with HIV, who received a stem cell transplant from an unrelated donor to treat acute myelogenous leukemia, has been in remission from both diseases since 2019.
<1
...
456789101112
...
31>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo